Drug Trial Radar · NCT00091832
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jan 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
255
Actual
Start
Sep 2004
Primary completion
Nov 2005
Study completion Oct 2006
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Sep 21, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.
Conditions
- Breast Cancer
- Metastases
- Bone Metastases in Subjects With Advanced Breast Cancer
Interventions
DenosumabBiological
Denosumab administered by subcutaneous injection
IV BisphosphonatesDrug
Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)Time frame: Baseline and Week 13
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.